Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 140

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 140
---
 adjusted basis as of June 30, 2025, the number of shares of common stock purchased or to be purchased from us, the total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculation below is based on the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our existing stockholders paid.

|                       |     | Shares Purchased 
 Number           |     | Percent |     |   |     | Total Consideration 
 Amount              |   |     | Percent |     |   |     | Weighted- 
 Average   
 Price Per 
 Share     |
|:----------------------|:----|:-----------------|:----|:--------|----:|:--|:----|:--------------------|:--|:----|:--------|----:|:--|:----|:----------|
| Existing stockholders |     |                  |     |         |     | % |     | $                   |   |     |         |     | % |     | $         |
| New investors(1)      |     |                  |     |         |     |   |     |                     |   |     |         |     |   |     |           |
| Total                 |     |                  |     |         | 100 | % |     |                     | $ |     |         | 100 | % |     |           |

| (1) | The presentation in this table regarding ownership by existing stockholders does not give effect to any 
 purchases that existing stockholders may make in this offering.                                         |

Each $1.00 increase (decrease) in the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors in this offering by $ million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Similarly, each 1.0 million share increase (de